The study (Res-05-0002) is a randomized, double-blind trial of reslizumab versus placebo in the treatment of pediatric patients between five and 18 years of age with poorly-controlled EE.
Under the terms of the agreement, Amgen will make an upfront payment to Kyowa Hakko of $100 million. Kyowa Hakko could receive up to $420 million in additional
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of July 21, 2008. The FDA has indicated that it does not expect to take
The company also announced the appointments of two new directors, Marian Gorecki and Steven Rubin, and the departures of current board chairman and director Eugene Bauer and current
The new facility will be in the Sorrento Valley and will house the company’s research, preclinical and clinical development, pharmaceutical sciences and administrative operations. Barry Quart, president and
The investment was led by the TPG Biotechnology II fund with participation from existing investors, including MedVenture Associates, Thomas Fogarty and Emergent Ventures, and Lava Ventures. Sleep Solutions
The company will negotiate for the manufacture, testing and packaging of a revised line of health promotion supplements with a tie-in to some of the company’s other interests.
The patent covers Symplex, Symphogen’s proprietary process for discovering antibodies with diversity and specificity customized to a particular therapeutic application. The granted European patent is effective in 33
In the placebo-controlled ICARE study, more than 3,000 patients were tested for Haptoglobin phenotype, and the 801 patients who had the Hp2-2 phenotype and were also taking statins
Alta Partners and Healthcare Ventures led the round as part of an investor syndicate that included New Enterprise Associates and Polaris Venture Partners. The company will use the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.